Schedule 13D ownership disclosure

Sionna Therapeutics Inc

Common Stock · CUSIP: 829401108

Event date: 2025-10-16

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Atlas Venture Fund XI, L.P.Reported CIK 0001708269

    Shares: 2,382,495.00 · Class: 5.4%

  • Atlas Venture Associates XI, L.P.Reported CIK 0001780068

    Shares: 2,382,495.00 · Class: 5.4%

  • Atlas Venture Associates XI, LLCReported CIK 0001780067

    Shares: 2,382,495.00 · Class: 5.4%

  • Atlas Venture Opportunity Fund II, L.P.Reported CIK 0001885327

    Shares: 701,985.00 · Class: 1.6%

  • Atlas Venture Associates Opportunity II, LPReported CIK 0001935814

    Shares: 701,985.00 · Class: 1.6%

  • Atlas Venture Associates Opportunity II, LLCReported CIK 0001935810

    Shares: 701,985.00 · Class: 1.6%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001708269-25-000004
Form type
SCHEDULE 13D/A
Filer
Atlas Venture Fund XI, L.P.
CIK
CIK 1708269
Filed
Oct 20, 2025
Reporting period
Oct 16, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub